

## P&T Motion History ADHD

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate	Reiteration of Prior Motion	Decision
<p>amphetamine* mixed amphetamine salts atomoxetine HCL clonidine HCL dexamethylphenidate HCL dextroamphetamine sulfate guanfacine HCL lisdexamfetamine dimesylate methamphetamine HCL methylphenidate methylphenidate HCL:</p> <ul style="list-style-type: none"> <li>• <b>Aptensio XR*</b></li> <li>• <b>QuilliChew ER*</b></li> </ul>	<p>After considering the evidence of safety, efficacy and special populations for the treatment of Attention Deficit Hyperactivity Disorder (ADHD), I move that methylphenidate based and amphetamine based agents of both long and short acting formulations are safe and efficacious. A long and short acting formulation of each stimulant should be preferred drugs on the Washington State Preferred Drug List. No single stimulant medication is associated with fewer adverse events in special populations. The stimulants listed above shall not be subject to therapeutic interchange on the Washington Preferred Drug List.</p> <p>After considering the evidence of safety efficacy and special populations for the treatment of Attention Deficit Hyperactivity Disorder (ADHD), I move that the non-stimulant atomoxetine is safe and efficacious and should be included as a preferred drug on the Washington State Preferred Drug List.</p> <p>After considering the evidence of safety efficacy and special populations for the treatment of Attention Deficit Hyperactivity</p>	August 17, 2016	Yes Johnson Chew	Yes Johnson Sanderson	Passed unanimous

**Bold** = new this update

\*new drug identified in scan not eligible for inclusion on PDL.

**P&T Motion History**  
**ADHD**

	Disorder (ADHD), I move that the alpha agonists clonidine and guanfacine are safe and efficacious and that one of these agents should be included as a preferred drug on the Washington State Preferred Drug List. Motion: Gaster 2 <sup>nd</sup> : Cordy				
--	---	--	--	--	--

**Bold** = new this update

\*new drug identified in scan not eligible for inclusion on PDL.

**7/13/2011**